The future of C4 Therapeutics hinges on the clinical advancement of its proprietary TORPEDO platform and targeted protein degradation pipeline. As the company moves its lead oncology candidates through clinical trials, its strategic trajectory centers on expanding collaborative partnerships with major pharmaceutical players, validating novel degradation pathways for challenging protein targets, and securing additional capital to support ongoing research and development milestones in precision medicine.